Targeted drug shows promise against rare leukemia
NCT ID NCT01711632
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called vemurafenib (Zelboraf) in 36 people with hairy cell leukemia that had returned or not responded to standard therapy. The goal was to see how well the drug could clear leukemia from the blood and what side effects it caused. Vemurafenib works by blocking a specific protein (BRAF) that helps the cancer grow.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Northwestern University
Evanston, Illinois, 60208, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Scripps Clinic
La Jolla, California, 92037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a Two-Drug combo beat back Tough-to-Treat hairy cell leukemia?
- New drug duo aims to tackle rare leukemia
- New registry aims to unlock secrets of rare leukemia
- Engineered immune cells take aim at stubborn blood cancers
- New combo therapy targets rare blood cancer in early trial